2021 Recorded Consultant Pharmacist Update- Medication Management for the Older Adult - Dr. McCoy - SGLT-2 Inhibitors for Treatment of Heart Failure and Chronic Kidney Disease
Large clinical trials involving patients with type 2 diabetes have shown that sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of heart failure hospitalizations by 30 to 35% and progression of renal disease by 35 to 50%. These cardiorenal benefits seem to be independent of glucose lowering capabilities by this class of medications. This presentation will evaluate the current evidence for use of SGLT2i in patients with heart failure (HF) and chronic kidney disease (CKD) both with and without type 2 diabetes, review pertinent HF and CKD guideline recommendations, and identify patients with HF and CKD who would be appropriate candidates for SGLT2i therapy.
This knowledge-based program is intended for pharmacists.
- Evaluate the current evidence for use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in the treatment of heart failure and/or chronic kidney disease.
- Discuss pertinent guideline recommendations regarding the use of SGLT2i in patients with heart failure and/or chronic kidney disease.
- Identify patients with heart failure and/or chronic kidney disease who would be appropriate candidates for treatment with SGLT2i therapy.
Auburn University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education; credits are recognized nationwide. The Universal Activity Number for this knowledge-based program is 0001-0000-21-022-H01-P and is intended for pharmacists. The initial release date for this home-study program is September 16, 2021 and the intended expiration date is September 16, 2024
- 1.00 ACPE PharmacyAuburn University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education; credits are recognized nationwide.